177 related articles for article (PubMed ID: 27758888)
41. Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.
Artigalás O; Vanni T; Hutz MH; Ashton-Prolla P; Schwartz IV
BMC Med; 2015 Jun; 13():139. PubMed ID: 26067721
[TBL] [Abstract][Full Text] [Related]
42. Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Chapman JA; Shepherd LE; Ingle JN; Muss HB; Pritchard KI; Gelmon KA; Whelan TJ; Elliott C; Goss PE
Breast Cancer Res Treat; 2016 Apr; 156(2):343-9. PubMed ID: 27006189
[TBL] [Abstract][Full Text] [Related]
43. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
[TBL] [Abstract][Full Text] [Related]
44. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
Lui A; New J; Ogony J; Thomas S; Lewis-Wambi J
BMC Cancer; 2016 Jul; 16():487. PubMed ID: 27421652
[TBL] [Abstract][Full Text] [Related]
45. CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.
Rodríguez-Sanz M; García-Giralt N; Prieto-Alhambra D; Servitja S; Balcells S; Pecorelli R; Díez-Pérez A; Grinberg D; Tusquets I; Nogués X
J Mol Endocrinol; 2015 Aug; 55(1):69-79. PubMed ID: 26108486
[TBL] [Abstract][Full Text] [Related]
46. A gene-to-gene interaction between aromatase and estrogen receptors influences bone mineral density.
Riancho JA; Zarrabeitia MT; Valero C; Sañudo C; Mijares V; González-Macías J
Eur J Endocrinol; 2006 Jul; 155(1):53-9. PubMed ID: 16793950
[TBL] [Abstract][Full Text] [Related]
47. Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.
Dudenkov TM; Liu D; Cairns J; Devarajan S; Zhuang Y; Ingle JN; Buzdar AU; Robson ME; Kubo M; Batzler A; Barman P; Jenkins GD; Carlson EE; Goetz MP; Northfelt DW; Moreno-Aspitia A; Desta Z; Reid JM; Kalari KR; Wang L; Weinshilboum RM
Clin Pharmacol Ther; 2019 Jul; 106(1):219-227. PubMed ID: 30648747
[TBL] [Abstract][Full Text] [Related]
48. Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.
Reinbolt RE; Sonis S; Timmers CD; Fernández-Martínez JL; Cernea A; de Andrés-Galiana EJ; Hashemi S; Miller K; Pilarski R; Lustberg MB
Cancer Med; 2018 Jan; 7(1):240-253. PubMed ID: 29168353
[TBL] [Abstract][Full Text] [Related]
49. Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.
Dempsey JM; Xi J; Henry NL; Rae JM; Hertz DL
Physiol Genomics; 2018 Feb; 50(2):98-99. PubMed ID: 29212847
[TBL] [Abstract][Full Text] [Related]
50. Personalizing aromatase inhibitor therapy in patients with breast cancer.
Hamadeh IS; Patel JN; Rusin S; Tan AR
Cancer Treat Rev; 2018 Nov; 70():47-55. PubMed ID: 30086432
[TBL] [Abstract][Full Text] [Related]
51. Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.
Liang Y; Gersch CL; Lehman J; Henry NL; Smith KL; Rae JM; Stearns V; Hertz DL
Pharmacogenet Genomics; 2024 Jun; 34(4):126-129. PubMed ID: 38359166
[TBL] [Abstract][Full Text] [Related]
52. Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using human lymphoblastoid cell lines.
Niu N; Liu T; Cairns J; Ly RC; Tan X; Deng M; Fridley BL; Kalari KR; Abo RP; Jenkins G; Batzler A; Carlson EE; Barman P; Moran S; Heyn H; Esteller M; Wang L
Hum Mol Genet; 2016 Nov; 25(21):4819-4834. PubMed ID: 28173075
[TBL] [Abstract][Full Text] [Related]
53. Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.
Sini V; Botticelli A; Lunardi G; Gori S; Marchetti P
Pharmacogenomics; 2017 Jun; 18(8):821-830. PubMed ID: 28592202
[TBL] [Abstract][Full Text] [Related]
54. Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study.
Wang L; Ingle J; Weinshilboum R
Clin Pharmacol Ther; 2018 Feb; 103(2):243-252. PubMed ID: 29052219
[TBL] [Abstract][Full Text] [Related]
55. GABC: A comprehensive resource and Genome Atlas for Breast Cancer.
Zhang Y; Wang P; Li X; Ning S; Li X; Cao Y; Chen SX
Int J Cancer; 2021 Feb; 148(4):988-994. PubMed ID: 33064305
[TBL] [Abstract][Full Text] [Related]
56. Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors.
Nevedomskaya E; Wessels L; Zwart W
Genom Data; 2014 Dec; 2():195-8. PubMed ID: 26484094
[TBL] [Abstract][Full Text] [Related]
57. Immune Mediator Pharmacogenomics:
Ho MF; Weinshilboum RM
J Nat Sci; 2017 Aug; 3(8):. PubMed ID: 28868359
[TBL] [Abstract][Full Text] [Related]
58. SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
Dudenkov TM; Ingle JN; Buzdar AU; Robson ME; Kubo M; Ibrahim-Zada I; Batzler A; Jenkins GD; Pietrzak TL; Carlson EE; Barman P; Goetz MP; Northfelt DW; Moreno-Aspita A; Williard CV; Kalari KR; Nakamura Y; Wang L; Weinshilboum RM
Breast Cancer Res Treat; 2017 Jul; 164(1):189-199. PubMed ID: 28429243
[TBL] [Abstract][Full Text] [Related]
59. Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
Cairns J; Ingle JN; Dudenkov TM; Kalari KR; Carlson EE; Na J; Buzdar AU; Robson ME; Ellis MJ; Goss PE; Shepherd LE; Goodnature B; Goetz MP; Weinshilboum RM; Li H; Bari MG; Wang L
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32701512
[TBL] [Abstract][Full Text] [Related]
60. The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.
Cairns J; Ingle JN; Kalari KR; Shepherd LE; Kubo M; Goetz MP; Weinshilboum RM; Wang L
Breast Cancer Res; 2019 Apr; 21(1):47. PubMed ID: 30944027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
